Literature DB >> 19056493

Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.

Arthur Okumu1, Marie DiMaso, Raimar Löbenberg.   

Abstract

PURPOSE: The purpose of this study was to compare the dissolution behaviour of etoricoxib in different dissolution media and to establish in vitro/in vivo correlation (IVIVC) using computer simulations.
METHODS: Drug solubility was measured in different media. The dissolution behaviour of etoricoxib was studied in the USP Apparatus 2 using different dissolution media. A dissolution transfer model was used to investigate if the drug stays in solution when the pH of the medium changes. Drug permeability assessment was performed using the caco-2 cell culture technique. The in vitro data were used as input functions in GastroPlus to simulate the in vivo profiles of the drug.
RESULTS: Solubility of etoricoxib was highest at low pH, and there was no significant difference in the solubility observed between blank buffers and biorelevant media of similar pH. The drug remained solubilised when transferred into simulated intestinal fluids. Using the in vitro data as input function in Gastro Plus, an IVIVC was established. Further simulations confirmed that the drug absorption occurs similar to the absorption of an oral solution.
CONCLUSIONS: Due to the solubility behaviour within the physiological pH gradient of the gastrointestinal tract, etoricoxib can be classified as an intermediate class 1/2 drug rather than BCS class 2. In vitro results combined with in silico simulations using GastroPlus support scientifically that a biowaiver for immediate release etoricoxib solid oral dosage forms is justified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19056493     DOI: 10.1016/j.ejpb.2008.10.019

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  20 in total

Review 1.  The use of modeling tools to drive efficient oral product design.

Authors:  Neil R Mathias; John Crison
Journal:  AAPS J       Date:  2012-05-30       Impact factor: 4.009

2.  Developing in vitro-in vivo correlation of risperidone immediate release tablet.

Authors:  Yardi Saibi; Hitoshi Sato; Hidehisa Tachiki
Journal:  AAPS PharmSciTech       Date:  2012-06-14       Impact factor: 3.246

Review 3.  Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.

Authors:  Amitava Mitra; Yunhui Wu
Journal:  AAPS J       Date:  2012-06-09       Impact factor: 4.009

4.  In vitro-in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation.

Authors:  Sandra Grbic; Jelena Parojcic; Svetlana Ibric; Zorica Djuric
Journal:  AAPS PharmSciTech       Date:  2010-12-23       Impact factor: 3.246

5.  General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.

Authors:  Feng Deng; Veli-Pekka Ranta; Heidi Kidron; Arto Urtti
Journal:  Pharm Res       Date:  2016-07-18       Impact factor: 4.200

6.  In vitro-in vivo correlation of efavirenz tablets using GastroPlus®.

Authors:  Thiago da Silva Honório; Eduardo Costa Pinto; Helvécio Vinicius A Rocha; Valeria Sant'Anna Dantas Esteves; Tereza Cristina dos Santos; Helena Carla Rangel Castro; Carlos Rangel Rodrigues; Valeria Pereira de Sousa; Lucio Mendes Cabral
Journal:  AAPS PharmSciTech       Date:  2013-08-14       Impact factor: 3.246

7.  Use of in vitro-in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices.

Authors:  Tahseen Mirza; Srikant A Bykadi; Christopher D Ellison; Yongsheng Yang; Barbara M Davit; Mansoor A Khan
Journal:  Pharm Res       Date:  2012-08-22       Impact factor: 4.200

8.  Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets.

Authors:  Amitava Mitra; Filippos Kesisoglou; Peter Dogterom
Journal:  AAPS PharmSciTech       Date:  2014-09-03       Impact factor: 3.246

9.  Utility of physiologically based absorption modeling in implementing Quality by Design in drug development.

Authors:  Xinyuan Zhang; Robert A Lionberger; Barbara M Davit; Lawrence X Yu
Journal:  AAPS J       Date:  2011-01-05       Impact factor: 4.009

10.  Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.

Authors:  Lisa Felden; Carmen Walter; Carlo Angioni; Yannick Schreiber; Nils von Hentig; Nerea Ferreiros; Gerd Geisslinger; Jörn Lötsch
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.